Biologics Discovery

Accelerating Discovery: Development of a High-throughput Mammalian Expression Platform as Part of a Fully Integrated Biologics Workflow

Tuesday, February 6
11:30 AM - 12:00 PM
Location: 7AB

The success of antibody discovery relies heavily on the ability to interrogate large, diverse antibody pools. However, the number of clones that can be screened for function is often limited by the capacity to express a large numbers of proteins at concentrations adequate for downstream cell-based assays. Bottlenecks in expression typically diminish success rates and often require project teams to re-initiate antibody discovery campaigns resulting in delays in timelines.
At the Lilly Biotechnology Center in San Diego, we have established a workflow utilizing both integrated automation systems, as well as stand-alone equipment, to overcome the limitations of throughput in the discovery of protein therapeutics. This “Islands of Automation” approach was strategically designed to allow for maximal flexibility in the incorporation of future antibody discovery technologies, as well as for cost efficiencies. Furthermore, this approach allows for intermittent quality control checks as well as parsing of plates either directly to project teams or to the next workstation.
At the centerpiece is a high-throughput mammalian expression platform, capable of performing ~4000 small-scale transient transfections/day. This system, built in collaboration with Wako Automation, evolved from a semi-automated process and this conversion required careful consideration of equipment selection, consumables cost, custom engineering as well as process redundancy to ensure minimal downtime. We have also streamlined this workflow to accommodate multiple plate types via a simple barcoding system and dynamic allocation of plates to cytomat shakers, effectively increasing efficiency, reducing FTE time and lowering reagent costs.
The expression platform requires communication with both upstream and downstream automation systems for seamless data tracking, accomplished through linkages with Beckman Coulter’s DART (Data Acquisition and Reporting Tool) and our in-house LIMS. In addition, evaluation of the overall workflow across the integrated automation systems identified key bottlenecks that were addressed through purchases and enablement of key stand-alone instruments.

Melissa Crisp

Senior Research Scientist, Automation
Eili Lilly and Company

Melissa received her Ph.D. in Molecular Cell Biology from the University of Florida. At the Scripps Florida Molecular Screening Center, she conducted miniaturized, ultra-high-throughput 1536-well screening campaigns across diverse biological platforms, in collaboration with both academic and industrial partners. Melissa is currently a Senior Research Scientist, Biologics Automation at Eli Lilly & Company, where she leads a team that draws on expertise in both assay development and automation to enhance automated workflow, implement new technologies and perform high-throughput functional screens to support drug discovery for biotherapeutics.

Presentation(s):

Send Email for Melissa Crisp


Assets

Accelerating Discovery: Development of a High-throughput Mammalian Expression Platform as Part of a Fully Integrated Biologics Workflow



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Accelerating Discovery: Development of a High-throughput Mammalian Expression Platform as Part of a Fully Integrated Biologics Workflow